Jonathan Schwartz - Mar 25, 2024 Form 3 Insider Report for ROCKET PHARMACEUTICALS, INC. (RCKT)

Role
Chief Medical & Gene Therapy Officer Exhibit 24: Power of Attorney
Signature
/s/ Martin Wilson, as attorney-in-fact for Jonathan Schwartz
Stock symbol
RCKT
Transactions as of
Mar 25, 2024
Transactions value $
$0
Form type
3
Date filed
4/3/2024, 06:07 PM
Previous filing
Nov 14, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding RCKT Common Stock 172K Mar 25, 2024 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding RCKT Stock Option (Right to Buy) Mar 25, 2024 Common Stock 60K $18.75 Direct F3
holding RCKT Stock Option (Right to Buy) Mar 25, 2024 Common Stock 75K $14.56 Direct F3
holding RCKT Stock Option (Right to Buy) Mar 25, 2024 Common Stock 30K $10.85 Direct F3
holding RCKT Stock Option (Right to Buy) Mar 25, 2024 Common Stock 75K $22.72 Direct F3
holding RCKT Stock Option (Right to Buy) Mar 25, 2024 Common Stock 7K $23.89 Direct F3
holding RCKT Stock Option (Right to Buy) Mar 25, 2024 Common Stock 35K $62.32 Direct F3
holding RCKT Stock Option (Right to Buy) Mar 25, 2024 Common Stock 81K $19.05 Direct F3
holding RCKT Stock Option (Right to Buy) Mar 25, 2024 Common Stock 124K $20.04 Direct F3
holding RCKT Stock Option (Right to Buy) Mar 25, 2024 Common Stock 57.3K $30.01 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents 95,726 shares of the Issuer's common stock and 78,687 Restricted Stock Units ("RSUs") that convert to common stock on a one-for-one basis.
F2 Includes unvested RSUs from grants of (i) 19,418 RSUs on February 16, 2024, (ii) 41,541 RSUs on February 14, 2023, and (iii) 25,984 RSUs on February 14, 2022; one-third of such RSUs granted vest on the first anniversary of the grant date and the remaining two-thirds vest in equal quarterly installments over the following two years. Includes a grant of 22,896 RSUs on August 12, 2022, all of which vest on August 12, 2025.
F3 This option represents a right to purchase shares of the Issuer's common stock, one-third become fully vested and exercisable on the first anniversary of the grant date, with the remaining shares vesting in equal quarterly installments over the following two years, subject to the reporting person's continued employment with the Issuer.

Remarks:

Chief Medical & Gene Therapy Officer Exhibit 24: Power of Attorney